ClinicalTrials.gg
CompletedNCT04502095Updated Sep 29, 2026Results posted

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

A Phase 4 interventional study of Clindamycin and Diary in Bladder Carcinoma, Refractory Bladder Carcinoma and Urinary Tract Infection, sponsored by Roswell Park Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Roswell Park Cancer Institute · Phase 4, Interventional, and Treatment

How we know

Updated Sep 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Enrollment
230th of 715
89 · median 46
Started
2020
with 52 others
Phase 4
7 of 883
1 open now
Registered
607th of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 230th largest by enrollment of the 715 interventional ones that give a count, is one of 53 that started in 2020, is one of 7 in phase 4, and was the 607th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if the utilization of a prophylactic antibiotic during the postoperative period will decrease the rate of urinary tract infection (UTI) post robot-assisted radical cystectomy.

SECONDARY OBJECTIVE:

I. To identify pre- and post-operative factors that may be associated with the development of a 90-day UTI following radical cystectomy.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (ANTIBIOTIC): Patients receive ertapenem Intravenously (IV), levofloxacin, or clindamycin IV at induction per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.

GROUP II (CONTROL): Patients receive ertapenem IV, levofloxacin IV or clindamycin IV at induction per standard of care.

After surgery, patients are followed up to 120 days.

03

Conditions studied

  • Bladder Carcinoma
  • Refractory Bladder Carcinoma
  • Urinary Tract Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient that electively chooses to have a cystectomy is eligible to participate in the study. Indications for a person who may undergo a cystectomy include having a diagnosis of muscle-invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC)
  • Any patient that will electively choose to have a robot-assisted radical cystectomy and is able to provide consent
  • Participant or legal representative must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of myasthenia gravis
  • Patients with a history of or taking other drugs that prolong corrected QTc (QTc) should be excluded
  • Patients with renal dysfunction, (mL/min) \< 30
  • Pregnant or nursing female participants
  • Females who receive a fertile sex sparing robot-assisted radical cystectomy (RARC)
  • Unwilling or unable to follow protocol requirements
  • Patients who receive a prophylactic antibiotic or antibiotic for any other reason prior to discharge
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)

    Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.

    Drug: Clindamycin · Other: Diary · Drug: Ertapenem · Drug: Levofloxacin · Drug: Nitrofurantoin · Drug: Trimethoprim-Sulfamethoxazole

  • Active comparator
    Group II (standard of care)

    Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.

    Drug: Clindamycin · Drug: Ertapenem · Drug: Levofloxacin

Interventions

  • Given PO

    Also known as: Cleocin

  • OtherDiary

    Complete drug diary

  • Given PO

  • Given PO

    Also known as: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1), Levaquin, Levofloxacin Hydrate, Quixin

  • Given PO

    Also known as: Macrobid, Macrodantin

  • DrugTrimethoprim-Sulfamethoxazole

    Given PO

    Also known as: Bactrim, Bactrim DS, Bactrimel, Centran, Centrin, Co-Trimoxazole, Cotrim, Cotrimoxazole, Eslectin, Insozalin, Septra, SMZ-TMP, Sulfamethoprim, Sulfatrim, Sulmeprim, TMP-SMX, Trimedin, Trimezole, Uroplus

06

What researchers measure

Primary outcomes

  1. Number of Participants With Urinary Tract Infection (UTI)

    The number of paticipants who experienced UTI (primary outcome) within 90 days after cystectomy is reported for each group.

    Time frame: At 90 days after surgery

Secondary outcomes

  1. Number of Participants With Infection

    Number of participants who experienced infectious complication(s) within 90 days after cystectomy is reported for each group. This includes UTI (primary outcome) and other types of infections, such as intraabdominal infection, wound infection, fungal infection, etc.

    Time frame: Up to 90 days after surgery

07

Results

Posted Sep 29, 2026
Limitations and caveats
* 1 The antibiotics chosen for prophylaxis were selected based on institutional data, and therefore, might vary from others. * 2 Patients who were discharged with drugs that may cause QT prolongation, or discharged on antibiotics, were not evaluated in current study. * 3 The lack of a placebo in the control group and also the clinicians being not blinded to the treatment group might have introduced some bias. * 4 Despite randomization, more females were included in the standard of care group.

Participant flow

The length of the recruitment ranges from 2020 to 2023, it is about 4 years. We recruited our patients in our department in Roswell Park Comprehensive Cancer Center. Patients who were scheduled cystectomy and eligible for this protocol were consented.

Participant flow — Overall Study
MilestoneGroup II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)
Started4544
Completed4037
Not completed57

Outcome measures

PrimaryNumber of Participants With Urinary Tract Infection (UTI)

The number of paticipants who experienced UTI (primary outcome) within 90 days after cystectomy is reported for each group.

Time frame:
At 90 days after surgery
Reported as:
Count of participants · Participants
Number of Participants With Urinary Tract Infection (UTI)
ParticipantsGroup II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)
Number of Participants With Urinary Tract Infection (UTI)100
SecondaryNumber of Participants With Infection

Number of participants who experienced infectious complication(s) within 90 days after cystectomy is reported for each group. This includes UTI (primary outcome) and other types of infections, such as intraabdominal infection, wound infection, fungal infection, etc.

Time frame:
Up to 90 days after surgery
Reported as:
Count of participants · Participants
Number of Participants With Infection
ParticipantsGroup II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)
Number of Participants With Infection175

Adverse events

Collected over Day of Cystectomy to Day 90 postop.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group II (Standard of Care)5/40 (12.5%)16/40 (40%)18/40 (45%)
Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)0/37 (0%)8/37 (21.6%)24/37 (64.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventGroup II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)
Small Bowel ObstructionGastrointestinal disorders3/400/37
Urinary LeakageRenal and urinary disorders1/402/37
Acute Kidney InjuryRenal and urinary disorders2/400/37
Intraabdominal Infection/AbscessInfections and infestations2/401/37
SepsisInfections and infestations2/400/37
Psychosis Confusion/DepressionNervous system disorders2/400/37
pleural effusionsRespiratory, thoracic and mediastinal disorders2/400/37
UTI (SAE)Infections and infestations2/400/37
Iatrogenic low rectal injuryGastrointestinal disorders0/401/37
Vesicovaginal FistulaRenal and urinary disorders0/401/37
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGroup II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)
UTI (Normal AE)Infections and infestations8/400/37
HyperkalemiaMetabolism and nutrition disorders4/406/37
MalnutritionMetabolism and nutrition disorders0/405/37
DiarrheaGastrointestinal disorders5/402/37
AnemiaMetabolism and nutrition disorders5/402/37
ArrhythmiaCardiac disorders2/404/37
AcidosisMetabolism and nutrition disorders4/404/37
DehydrationMetabolism and nutrition disorders2/404/37
Deep Venous ThrombosisVascular disorders3/402/37
Wound InfectionInfections and infestations2/400/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)Total
Median68 (64 to 77)70 (65 to 75)69 (65 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Group II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)Total
Female14519
Male263258
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group II (Standard of Care)Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin)Total
African American/Black033
Other Race/Ethnicity403171
08

Study locations

1 site
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
09

References and documents

Publications

  • Hussein AA, Mahmood AW, Ahmad A, Houenstein H, Harrington G, Khan M, Abdelhaq D, Jing Z, Attwood K, Almyroudis NG, Li Q, Guru KA. Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections After Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial. J Urol. 2025 Aug;214(2):147-155. doi: 10.1097/JU.0000000000004586. Epub 2025 Apr 25. PubMed 40279497 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2025, 54 months.

Results were first posted in Sep 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2020
First posted
Aug 6, 2020
StartActual
Sep 2, 2020
Primary completionActual
Mar 13, 2025
CompletionActual
Mar 13, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited90-day urinary tract infectionNumber of Participants With Urinary Tract Infection (UTI) statusTime frame: At 90 days after surgery
Sep 29, 2026
Documents
Secondary outcomes
1 added, 4 removed
What changed in the outcomes
  • AddedNumber of Participants With InfectionTime frame: Up to 90 days after surgery
  • RemovedIdentify pre-operative factors associated with the development of UTITime frame: Up to 120 days after surgery
  • RemovedDevelopment of Clostridium difficile (C Diff)Time frame: up to 120 days after surgery
  • RemovedInfections occurring during antibiotic useTime frame: Up to 120 days after surgery
  • RemovedIdentify post operative factors associated with the development of UTITime frame: Up to 120 days after surgery
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited90-day urinary tract infectionNumber of Participants With Urinary Tract Infection (UTI) statusTime frame: At 90 days after surgery
    Secondary outcomes 1 added, 4 removed
    What changed in the outcomes
    • AddedNumber of Participants With InfectionTime frame: Up to 90 days after surgery
    • RemovedIdentify pre-operative factors associated with the development of UTITime frame: Up to 120 days after surgery
    • RemovedDevelopment of Clostridium difficile (C Diff)Time frame: up to 120 days after surgery
    • RemovedInfections occurring during antibiotic useTime frame: Up to 120 days after surgery
    • RemovedIdentify post operative factors associated with the development of UTITime frame: Up to 120 days after surgery
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04502095
Responsible party
Sponsor
First posted
Aug 6, 2020
Start date
Sep 2, 2020
Primary completion
Mar 13, 2025
Completion
Mar 13, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Khurshid A Guru
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrofurantoin

Start the discussion